<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">BMC Neurol</journal-id>
      <journal-id journal-id-type="iso-abbrev">BMC Neurol</journal-id>
      <journal-title-group>
        <journal-title>BMC Neurology</journal-title>
      </journal-title-group>
      <issn pub-type="epub">1471-2377</issn>
      <publisher>
        <publisher-name>BioMed Central</publisher-name>
        <publisher-loc>London</publisher-loc>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">25403760</article-id>
      <article-id pub-id-type="pmc">4237783</article-id>
      <article-id pub-id-type="publisher-id">213</article-id>
      <article-id pub-id-type="doi">10.1186/s12883-014-0213-0</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Case Report</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Treatment of stroke related refractory brain edema using mixed vasopressin antagonism: a case report and review of the literature</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author" corresp="yes">
          <name>
            <surname>Hedna</surname>
            <given-names>Vishnumurthy Shushrutha</given-names>
          </name>
          <address>
            <email>v.hedna@neurology.ufl.edu</email>
          </address>
          <xref ref-type="aff" rid="Aff1"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Bidari</surname>
            <given-names>Sharathchandra</given-names>
          </name>
          <address>
            <email>bidars@radiology.ufl.edu</email>
          </address>
          <xref ref-type="aff" rid="Aff2"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Gubernick</surname>
            <given-names>David</given-names>
          </name>
          <address>
            <email>david.gubernick@ufl.edu</email>
          </address>
          <xref ref-type="aff" rid="Aff1"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Ansari</surname>
            <given-names>Saeed</given-names>
          </name>
          <address>
            <email>saeedansari81@yahoo.com</email>
          </address>
          <xref ref-type="aff" rid="Aff1"/>
          <xref ref-type="aff" rid="Aff3"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Satriotomo</surname>
            <given-names>Irawan</given-names>
          </name>
          <address>
            <email>isatriotomo@yahoo.com</email>
          </address>
          <xref ref-type="aff" rid="Aff1"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Khan</surname>
            <given-names>Asif A</given-names>
          </name>
          <address>
            <email>asifk63@gmail.com</email>
          </address>
          <xref ref-type="aff" rid="Aff4"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Qureshi</surname>
            <given-names>Adnan I</given-names>
          </name>
          <address>
            <email>qureshai@gmail.com</email>
          </address>
          <xref ref-type="aff" rid="Aff4"/>
        </contrib>
        <aff id="Aff1"><label/>Departments of Neurology, College of Medicine, University of Florida, Room L3-100, McKnight Brain Institute, 1149 Newell Drive, Gainesville, FL 32611 USA </aff>
        <aff id="Aff2"><label/>Radiology, University of Florida, Gainesville, FL USA </aff>
        <aff id="Aff3"><label/>Surgery, University of Florida, Gainesville, FL USA </aff>
        <aff id="Aff4"><label/>Department of Neurology, Central Care Health, St. Cloud, MN USA </aff>
      </contrib-group>
      <pub-date pub-type="epub">
        <day>18</day>
        <month>11</month>
        <year>2014</year>
      </pub-date>
      <pub-date pub-type="pmc-release">
        <day>18</day>
        <month>11</month>
        <year>2014</year>
      </pub-date>
      <pub-date pub-type="collection">
        <year>2014</year>
      </pub-date>
      <volume>14</volume>
      <elocation-id>213</elocation-id>
      <history>
        <date date-type="received">
          <day>16</day>
          <month>4</month>
          <year>2014</year>
        </date>
        <date date-type="accepted">
          <day>29</day>
          <month>10</month>
          <year>2014</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>&#xA9; Hedna et al.; licensee BioMed Central Ltd. 2014</copyright-statement>
        <license license-type="open-access">
          <license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0">http://creativecommons.org/licenses/by/4.0</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated.</license-p>
        </license>
      </permissions>
      <abstract id="Abs1">
        <sec>
          <title>Background</title>
          <p>Elevated intracranial pressure from cerebral edema is the major cause of early mortality in acute stroke. Current treatment strategies to limit cerebral edema are not particularly effective. Some novel anti-edema measures have shown promising early findings in experimental stroke models. Vasopressin antagonism in stroke is one such target which has shown some encouraging preliminary results. The aim of this report is to highlight the potential use of vasopressin antagonism to limit cerebral edema in patients after acute stroke.</p>
        </sec>
        <sec>
          <title>Case presentation</title>
          <p>A 57-year-old Caucasian man with new onset diplopia was diagnosed with vertebral artery aneurysm extending into the basilar circulation. He underwent successful elective vertebral artery angioplasty and coiling of the aneurysm. In the immediate post-operative period there was a decline in his neurological status and brain imaging revealed new midbrain and thalamic hemorrhage with surrounding significant brain edema. Treatment with conventional anti-edema therapy was initiated with no significant clinical response after which conivaptan; a mixed vasopressin antagonist was started. Clinical and radiological evaluation following drug administration showed rapid clinical improvement without identification of significant adverse effects.</p>
        </sec>
        <sec>
          <title>Conclusions</title>
          <p>The authors have successfully demonstrated the safety and efficacy of using mixed vasopressin antagonist in treatment of stroke related brain edema, thereby showing its promise as an alternative anti-edema agent. Preliminary findings from this study suggest mixed vasopressin antagonism may have significant utility in the management of cerebral edema arising from cerebrovascular accident. Larger prospective studies are warranted to explore the role of conivaptan in the treatment of brain edema and neuroprotection.</p>
        </sec>
      </abstract>
      <kwd-group xml:lang="en">
        <title>Keywords</title>
        <kwd>Cerebral edema</kwd>
        <kwd>Stroke</kwd>
        <kwd>Vasopressin</kwd>
        <kwd>Mixed vasopressin antagonism</kwd>
        <kwd>Conivaptan</kwd>
      </kwd-group>
      <custom-meta-group>
        <custom-meta>
          <meta-name>issue-copyright-statement</meta-name>
          <meta-value>&#xA9; The Author(s) 2014</meta-value>
        </custom-meta>
      </custom-meta-group>
    </article-meta>
  </front>
  <body>
    <sec id="Sec1" sec-type="introduction">
      <title>Background</title>
      <p>Stroke is the fourth leading cause of death in United States [<xref ref-type="bibr" rid="CR1">1</xref>]. Brain edema and herniation are implicated in the majority of these cases [<xref ref-type="bibr" rid="CR2">2</xref>]. No effective agents exist that have altered the management of brain edema to the satisfaction of clinicians involved in stroke care. Decompressive hemicraniectomy has reduced mortality in malignant middle cerebral artery (MCA) stroke, but only when used in younger populations within 48&#xA0;hours of symptom onset [<xref ref-type="bibr" rid="CR3">3</xref>]. In the neurocritical care setting, mannitol and hypertonic saline are used extensively for managing brain edema due to the lack of more effective options, rather than its therapeutic superiority [<xref ref-type="bibr" rid="CR4">4</xref>]. Significant controversy about the advantages and disadvantages of these agents in long term patient outcomes following brain edema further complicate the clinical picture [<xref ref-type="bibr" rid="CR5">5</xref>]. Hence there is a great need for alternative agents to rapidly decrease increased intracranial pressure as a result of stroke-related brain edema, thereby reducing brain herniation and its subsequent morbidity and mortality.</p>
      <p>Arginine-vasopressin (AVP), a potent endogenous hormone responsible for regulating plasma osmolality and volume, has demonstrated a role in the pathophysiological mechanisms in stroke [<xref ref-type="bibr" rid="CR6">6</xref>,<xref ref-type="bibr" rid="CR7">7</xref>]. Evidence of AVP&#x2019;s significant role in cerebral edema has made it a promising drug target in the management of this condition [<xref ref-type="bibr" rid="CR8">8</xref>]. Chang <italic>et al</italic>. found time-dependent increases in serum AVP levels after brain injury as well as attenuation of AVP levels following administration of 7.5% hypertonic saline in an experimental stroke model [<xref ref-type="bibr" rid="CR7">7</xref>]. These studies also found that osmotherapy is effective in reducing intracranial pressure (ICP) through a common AVP-mediated pathway.</p>
      <p>The mechanism of action of AVP is mainly mediated by 2 receptor subtypes: V1a and V2 which are expressed in the brain, pituitary gland, myocardium, vasculature and kidneys. Experimental models have demonstrated the utility of V1a and V2 AVP receptor antagonism in attenuation of ischemia related cerebral edema and infarct volume by aquaporin (AQP) 4 expression modulation. Even though appealing, the evidence for clinical utility of vasopressin antagonism in stroke related brain edema is sparse. Conivaptan is a mixed vasopressin receptor (V1a and V2) antagonist that belongs to the group of non-peptide vasopressin antagonists referred to as &#x201C;Vaptans&#x201D; [<xref ref-type="bibr" rid="CR9">9</xref>]. This class has been approved by Food and Drug Administration (FDA) for use in hypervolemic/euvolemic hyponatremia [<xref ref-type="bibr" rid="CR10">10</xref>].</p>
      <p>We report a case of a disabling stroke after an endovascular procedure who received conivaptan as last resort to reduce his brain edema. This patient&#x2019;s clinical course and radiological findings were serially monitored and recorded. Adverse events and safety data from this medication were also monitored and documented.</p>
    </sec>
    <sec id="Sec2">
      <title>Case presentation</title>
      <p>A 57-year-old Caucasian male with residual right-sided hemiparesis from a cerebrovascular event, 1&#xA0;month prior to this admission, presented with sudden onset of vision changes. He complained his vision was &#x201C;upside down&#x201D; with associated headache, nausea and vomiting. His past medical history included pacemaker implantation, and multiple sclerosis in remission. On neurological exam, his National Institutes of Health Stroke Scale (NIHSS) was 9 when including his previous residual neurological deficits. Higher cognitive function was mostly intact except for dysarthria, and diplopia on horizontal gaze with right internuclear opthalmoplegia. His old deficits from recent stroke included partial right facial palsy with right hemiparesis (motor system examinations using the Medical Research Council (MRC) grade: 2/5 in right upper and lower extremity), hemi body numbness and intact cerebellar function. Computed tomography (CT) scan of the head without contrast revealed left precentral gyrus hypodensity extending to the hand area, most consistent with an evolving late subacute infarct corresponding to the patient's right upper extremity weakness. Most prominent was the finding of a partially calcified 16&#xA0;mm fusiform aneurysm of the left vertebral artery (VA) with extension to the basilar junction and beyond. On day 1 of admission, he was complaining of severe intractable headaches and depression. On day 6, he had a sudden decline in his neurological exam wherein he developed complete facial weakness, became somnolent, and suffered a 25&#xA0;minutes generalized tonic clonic seizure (which was treated with a standard status epilepticus treatment regimen). Repeat head CT demonstrated new hypodensity in the mesial aspect of the left midbrain compared to the admission study. This was most consistent with a subacute infarct in the basilar perforator territory which explained the patient's double vision.</p>
      <p>Elective right vertebral artery angioplasty with aneurysm stenting of the vertebral artery was performed on day 13. Approximately 2&#xA0;hours after the procedure his left pupil became fixed and dilated. He developed dense hemiplegia on his left side. Stat head CT demonstrated interval development of acute hemorrhage in the mesial aspect of right thalamus measuring 11&#x2009;&#xD7;&#x2009;9&#xA0;mm in maximal axial dimensions. There was also hemorrhage seen in the central part of upper midbrain measuring 8&#x2009;&#xD7;&#x2009;8&#xA0;mm. A significant vasogenic edema surrounding the hematoma that extended up to the lower midbrain was seen (Figure&#xA0;<xref rid="Fig1" ref-type="fig">1</xref>A, B).<fig id="Fig1"><label>Figure 1</label><caption><p>
<bold>Imaging before conivaptan administration.</bold> The immediate post-procedure (intra-arterial stent insertion) CT head (without contrast) demonstrate acute hemorrhage in the right mesial thalamus <bold>(A)</bold> with surrounding mild vasogenic edema and hypodensity on both sides of mid brain <bold>(B)</bold>. The CT head (without contrast) before conivaptan administration reveals slight decrease in the density of acute hemorrhage in the right mesial thalamus, but with worsening surrounding vasogenic edema <bold>(C)</bold>. The hypodensity in the mid brain has also worsened without any normal density tissue visible, especially adjacent to the quadrigeminal cistern <bold>(D)</bold>.</p></caption><graphic xlink:href="12883_2014_213_Fig1_HTML" id="MO1"/></fig></p>
      <p>He was started on hypertonic saline with a target serum osmolality of 300&#x2013;320&#xA0;mOsm/kg and serum sodium goal of 150&#x2013;160&#xA0;mEq/L (post-operative sodium was 140&#xA0;mEq/L). On post-operative day 1, there was no change in his neurological exam as the patient remained unresponsive with left fixed, dilated pupil and no movement on his left upper and lower extremity. There was interval increase in the brain stem edema in comparison to brain imaging from the previous day (Figure&#xA0;<xref rid="Fig1" ref-type="fig">1</xref>C, D). Due to the lack of response from hypertonic saline, he was started on intravenous conivaptan. Conivaptan was administered as per the drug administration guidelines approved by FDA with 20&#xA0;mg infused over 30&#xA0;minutes as a loading dose, followed by a continuous infusion of 20&#xA0;mg over 24&#xA0;hours (0.83&#xA0;mg/hour) planned for 2&#xA0;days. On post-operative day 2, after 8&#xA0;hours of receiving the loading dose of conivaptan, patient started responding to commands and was seen moving his left upper and lower extremities. His sodium was 145&#xA0;mEq/L. In the next 2&#xA0;days he was showing significant progress on neurological exam, even demonstrating some strength in his left upper extremity. Repeat head CT on day 18 (after 2&#xA0;days of conivaptan administration) demonstrated expected hematoma density changes both within the mesial right thalamus and in the central midbrain, but the size of the hematoma was stable compared to prior examination. However, the perilesional edema had significantly decreased, most apparent in the upper and mid portion of the midbrain. The comparison of the imaging at the level of both thalamus (Figure&#xA0;<xref rid="Fig2" ref-type="fig">2</xref>A, B) and midbrain (Figure&#xA0;<xref rid="Fig2" ref-type="fig">2</xref>C, D) showed noticeable resolution of brain edema and restoration of some normal tissue after conivaptan administration. Despite making significant neurological improvements and tolerating extubation our patient subsequently developed respiratory failure presumably due to aspiration pneumonia and his family opted to shift to palliative care only.<fig id="Fig2"><label>Figure 2</label><caption><p>
<bold>Imaging after conivaptan administration.</bold> Comparative images at the level of thalamus pre <bold>(A)</bold> and post <bold>(B)</bold> conivaptan administration shows significant reduction in vasogenic edema (red arrows) with normal density appearing tissue seen in the ventral aspect of right thalamus following conivaptan administration (thick blue arrow). Moreover, comparative images at the level of mid brain pre <bold>(C)</bold> and post <bold>(D)</bold> conivaptan administration clearly demonstrate significantly reduced hypodensity (red arrows), especially adjacent to the quadrigeminal cistern. The normal density appearing tissue emerges following conivaptan administration (blue arrow heads).</p></caption><graphic xlink:href="12883_2014_213_Fig2_HTML" id="MO2"/></fig></p>
    </sec>
    <sec id="Sec3" sec-type="discussion">
      <title>Discussion</title>
      <p>Conivaptan is a mixed vasopressin antagonist, currently approved for euvolemic or hypervolemic hyponatremia in heart failure, which has shown tremendous promise in both experimental and clinical brain injury scenarios. It acts via both V1a and V2 receptors making it the only FDA approved mixed vasopressin antagonist [<xref ref-type="bibr" rid="CR9">9</xref>]. There is strong literature evidence to show V1a antagonism is useful in limiting vasopressin mediated brain damage after inducing stroke in animal models. The V1a antagonism was helpful in reducing brain edema via down-regulation of AQP-4 in these experiments [<xref ref-type="bibr" rid="CR11">11</xref>]. Since the V2 receptor mediates AVP expression via positive feedback, V2 antagonism may, in theory, be advantageous when formulating novel ligands for neuroprotection. In the neurocritical care literature, conivaptan has been used safely to reduce intracranial pressure, increase serum sodium to desired goal, and to augment cerebral perfusion pressure [<xref ref-type="bibr" rid="CR12">12</xref>,<xref ref-type="bibr" rid="CR13">13</xref>]. There is anecdotal evidence for its use in neurosurgical and cardiac intensive care unit (ICU) settings where it show promise in the treatment of hyponatremia secondary to traumatic brain injury and other conditions [<xref ref-type="bibr" rid="CR14">14</xref>,<xref ref-type="bibr" rid="CR15">15</xref>]. The most common side effects described for the short-term use of conivaptan include infusion site phlebitis, headaches, increased thirst, pyrexia and constipation. Orthostatic hypotension, hypokalemia, rebound hyponatremia, atrial dysrhythmias, and sepsis are other serious adverse effects. Contraindications for using conivaptan are hypovolemic hyponatremia and simultaneous use of CYP3A4 inhibitors [<xref ref-type="bibr" rid="CR13">13</xref>].</p>
      <p>During stroke, AVP is released from the posterior pituitary in response to histamine activation of magnocellular neurons in the hypothalamus AVP then interacts with its receptors V1a and V2 to mediate processes which lead to further cerebral edema. Antagonism of these receptors is described below:</p>
      <sec id="Sec4">
        <title>Role of V1a receptors in brain</title>
        <p>Vasopressin receptor V1a is involved in the pathogenesis of secondary brain damage following focal cerebral ischemia. The V1a receptor antagonism causes platelet inhibition, AQP-4 channel modulation, reduced infarct size and vasodilation. Also, V1a antagonists have been shown to prevent the development of ischemia-induced cerebral edema, thereby suggesting the importance of the V1a receptor interaction in water regulation in brain cells [<xref ref-type="bibr" rid="CR16">16</xref>-<xref ref-type="bibr" rid="CR18">18</xref>]. Further, vasopressin V1a receptor antagonism has largely been shown to improve outcomes after experimental stroke. A V1a antagonist SR49059, has been demonstrated to decrease rates of brain water accumulation at varying time points in intracerebral hemorrhage (ICH) [<xref ref-type="bibr" rid="CR19">19</xref>,<xref ref-type="bibr" rid="CR20">20</xref>]. This agent also reduced AQP-4 expression and led to decreased cerebral edema after ICH. The aforementioned antagonist was found to reduce cytotoxic brain edema via AQP-4 attenuation in an experimental model of middle cerebral artery occlusion (MCAO) [<xref ref-type="bibr" rid="CR11">11</xref>]. Hence, it appears that AQP-4 channels, which play a key role in development of brain edema, may be modulated by V1a antagonism [<xref ref-type="bibr" rid="CR9">9</xref>]. Other V1a antagonists have also shown similar effects in reducing brain water content after cold-induced edema in addition to dose-dependent decreases in the permeability of the blood&#x2013;brain barrier [<xref ref-type="bibr" rid="CR8">8</xref>]. The V1a antagonism mediated neuroprotection is postulated to occur via dampening of cerebrovasodilation, caused by ATP-sensitive and calcium-sensitive potassium channels, potentially leading to decreased reperfusion injury and vasogenic edema [<xref ref-type="bibr" rid="CR21">21</xref>]. Vakili <italic>et al</italic>. successfully demonstrated V1a antagonism resulted in a dose-dependent attenuation of infarct volume and blood&#x2013;brain barrier disruption and more importantly a decrease in brain edema [<xref ref-type="bibr" rid="CR8">8</xref>].</p>
      </sec>
      <sec id="Sec5">
        <title>Role of V2 receptors in brain</title>
        <p>The V2 receptor expression in the central nervous system is limited and the extent of its contribution in brain edema is thus controversial [<xref ref-type="bibr" rid="CR22">22</xref>]. Some studies demonstrate V2 receptor antagonism may act by decreasing AVP release through a negative feedback mechanism [<xref ref-type="bibr" rid="CR23">23</xref>,<xref ref-type="bibr" rid="CR24">24</xref>]. Recently, a few studies have demonstrated that the V2 receptor antagonist, OPC-31260, may be effective in the early treatment of cytotoxic edema and brain injury [<xref ref-type="bibr" rid="CR18">18</xref>,<xref ref-type="bibr" rid="CR25">25</xref>]. Administration of OPC-31260 ameliorated cerebral neurological deficit in transgenic mice overexpressing endothelin-1 in astrocytes (GET-1) after water intoxication. Treatment with OPC-31260 also significantly decreased water accumulation and down-regulated AQP-4 expression levels in GET-1 mice after water intoxication. In fact, AQP-4 levels were shown to almost be completely normal when comparing AQP-4 staining intensity in GET-1 mice with and without water intoxication. It was also shown that administration of OPC-31260 at doses of 10 to 30&#xA0;mg/kg led to a dose-dependent inhibition of subarachnoid hemorrhage-induced cerebral edema formation, accompanied by an increase in urinary volume and decrease in urine osmolality without a significant alteration of urine electrolytes [<xref ref-type="bibr" rid="CR26">26</xref>]. The V2 receptor antagonism also helped diminish water accumulation, decreased glial fibrillary acidic protein (GFAP) in astrocytes, and most importantly led to a renal tubule-selective diuretic effect called aquaresis (electrolyte sparing diuresis), which may have additional benefits in the reduction of cerebral edema [<xref ref-type="bibr" rid="CR12">12</xref>].</p>
        <p>To further explore the exciting promise of Conivaptan&#x2019;s use in stroke and brain edema, we have developed an experimental murine stroke model [<xref ref-type="bibr" rid="CR27">27</xref>]. Early results from this study have been promising. We have demonstrated that conivaptan ameliorated brain swelling at two early time points (12&#xA0;h and 24&#xA0;h) by more than 50% in comparison to control in MCAO. At 12&#xA0;h, ipsilateral average hemispheric edema (HE%) in the conivaptan-treated group (n&#x2009;=&#x2009;16) was 6.64&#x2009;&#xB1;&#x2009;1.62% versus 16.55&#x2009;&#xB1;&#x2009;1.76% in controls (n&#x2009;=&#x2009;16, p&#x2009;=&#x2009;0.0003). This was reproduced at 24&#xA0;h, where HE% in the conivaptan-treated group (n&#x2009;=&#x2009;12) was 6.81&#x2009;&#xB1;&#x2009;1.33% in comparison to 13.93&#x2009;&#xB1;&#x2009;1.57% in the control group (n&#x2009;=&#x2009;12, p&#x2009;=&#x2009;0.002). Our studies are underway to answer some questions about its mechanism of action in attenuation of brain edema by concentrating specifically on aquaporin channels and its ligands.</p>
      </sec>
    </sec>
    <sec id="Sec6" sec-type="conclusion">
      <title>Conclusions</title>
      <p>Brain edema contributes significantly to morbidity and death associated with stroke. However current option treatments are limited to hyperosmolar agents and surgical decompression. In this case report we describe the potential of the mixed vasopressin antagonist, conivaptan, in the acute treatment of brain edema. To our knowledge, this is the first case report in the literature describing the benefits of conivaptan use in clinical brain edema. Although this report is very encouraging, additional randomized clinical studies and caution is advised regarding its use until the result of more definitive trials investigating its safety and efficacy are known. We hope that this report highlights the inadequacy of standard treatment of cerebral edema and generates future studies which explore novel therapeutic agents, including larger studies to fully characterize the potential role of mixed vasopressin antagonism.</p>
    </sec>
    <sec id="Sec7">
      <title>Consent</title>
      <p>Written informed consent was obtained from the patient's next of kin for publication of this Case report and any accompanying images. A copy of the written consent is available for review by the Editor of this journal.</p>
    </sec>
  </body>
  <back>
    <glossary>
      <title>Abbreviations</title>
      <def-list>
        <def-list>
          <def-item>
            <term>MCA</term>
            <def>
              <p>Middle cerebral artery</p>
            </def>
          </def-item>
          <def-item>
            <term>MCAO</term>
            <def>
              <p>Middle cerebral artery occlusion</p>
            </def>
          </def-item>
          <def-item>
            <term>ICP</term>
            <def>
              <p>Intracranial pressures</p>
            </def>
          </def-item>
          <def-item>
            <term>AVP</term>
            <def>
              <p>Arginine-vasopressin</p>
            </def>
          </def-item>
          <def-item>
            <term>AQP</term>
            <def>
              <p>Aquaporin</p>
            </def>
          </def-item>
          <def-item>
            <term>FDA</term>
            <def>
              <p>Food and Drug Administration</p>
            </def>
          </def-item>
          <def-item>
            <term>NIHSS</term>
            <def>
              <p>National Institutes of Health Stroke Scale</p>
            </def>
          </def-item>
          <def-item>
            <term>MRC</term>
            <def>
              <p>Medical Research Council</p>
            </def>
          </def-item>
          <def-item>
            <term>CT</term>
            <def>
              <p>Computed tomography</p>
            </def>
          </def-item>
          <def-item>
            <term>VA</term>
            <def>
              <p>Vertebral artery</p>
            </def>
          </def-item>
          <def-item>
            <term>ICH</term>
            <def>
              <p>Intracerebral hemorrhage</p>
            </def>
          </def-item>
          <def-item>
            <term>HE</term>
            <def>
              <p>Hemispheric edema</p>
            </def>
          </def-item>
          <def-item>
            <term>ICU</term>
            <def>
              <p>Intensive care unit</p>
            </def>
          </def-item>
        </def-list>
      </def-list>
    </glossary>
    <fn-group>
      <fn>
        <p>
          <bold>Competing interests</bold>
        </p>
        <p>The authors declare that they have no competing interests.</p>
      </fn>
      <fn>
        <p>
          <bold>Authors&#x2019; contributions</bold>
        </p>
        <p>VSH, SA, DG and IS wrote the draft manuscript. SB prepared CT images and was involved in drafting the manuscript. VSH, AAK and AIQ initiated the study, reviewed and edited the manuscript, and approved the final version. All authors read and approved the final manuscript.</p>
      </fn>
    </fn-group>
    <ack>
      <p>No funding was provided for the production of this report.</p>
    </ack>
    <ref-list id="Bib1">
      <title>References</title>
      <ref id="CR1">
        <label>1.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Roger</surname>
              <given-names>VL</given-names>
            </name>
            <name>
              <surname>Go</surname>
              <given-names>AS</given-names>
            </name>
            <name>
              <surname>Lloyd-Jones</surname>
              <given-names>DM</given-names>
            </name>
            <name>
              <surname>Benjamin</surname>
              <given-names>EJ</given-names>
            </name>
            <name>
              <surname>Berry</surname>
              <given-names>JD</given-names>
            </name>
            <name>
              <surname>Borden</surname>
              <given-names>WB</given-names>
            </name>
            <name>
              <surname>Bravata</surname>
              <given-names>DM</given-names>
            </name>
            <name>
              <surname>Dai</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Ford</surname>
              <given-names>ES</given-names>
            </name>
            <name>
              <surname>Fox</surname>
              <given-names>CS</given-names>
            </name>
            <name>
              <surname>Fullerton</surname>
              <given-names>HJ</given-names>
            </name>
            <name>
              <surname>Gillespie</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Hailpern</surname>
              <given-names>SM</given-names>
            </name>
            <name>
              <surname>Heit</surname>
              <given-names>JA</given-names>
            </name>
            <name>
              <surname>Howard</surname>
              <given-names>VJ</given-names>
            </name>
            <name>
              <surname>Kissela</surname>
              <given-names>BM</given-names>
            </name>
            <name>
              <surname>Kittner</surname>
              <given-names>SJ</given-names>
            </name>
            <name>
              <surname>Lackland</surname>
              <given-names>DT</given-names>
            </name>
            <name>
              <surname>Lichtman</surname>
              <given-names>JH</given-names>
            </name>
            <name>
              <surname>Lisabeth</surname>
              <given-names>LD</given-names>
            </name>
            <name>
              <surname>Makuc</surname>
              <given-names>DM</given-names>
            </name>
            <name>
              <surname>Marcus</surname>
              <given-names>GM</given-names>
            </name>
            <name>
              <surname>Marelli</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Matchar</surname>
              <given-names>DB</given-names>
            </name>
            <name>
              <surname>Moy</surname>
              <given-names>CS</given-names>
            </name>
            <name>
              <surname>Mozaffarian</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Mussolino</surname>
              <given-names>ME</given-names>
            </name>
            <name>
              <surname>Nichol</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Paynter</surname>
              <given-names>NP</given-names>
            </name>
            <name>
              <surname>Soliman</surname>
              <given-names>EZ</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Executive summary: heart disease and stroke statistics&#x2013;2012 update: a report from the American Heart Association</article-title>
          <source>Circulation</source>
          <year>2012</year>
          <volume>125</volume>
          <issue>1</issue>
          <fpage>188</fpage>
          <lpage>197</lpage>
          <pub-id pub-id-type="doi">10.1161/CIR.0b013e3182456d46</pub-id>
          <pub-id pub-id-type="pmid">22215894</pub-id>
        </element-citation>
      </ref>
      <ref id="CR2">
        <label>2.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Hacke</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>Schwab</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Horn</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Spranger</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>De Georgia</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>von Kummer</surname>
              <given-names>R</given-names>
            </name>
          </person-group>
          <article-title>'Malignant' middle cerebral artery territory infarction: clinical course and prognostic signs</article-title>
          <source>Arch Neurol</source>
          <year>1996</year>
          <volume>53</volume>
          <issue>4</issue>
          <fpage>309</fpage>
          <lpage>315</lpage>
          <pub-id pub-id-type="doi">10.1001/archneur.1996.00550040037012</pub-id>
          <pub-id pub-id-type="pmid">8929152</pub-id>
        </element-citation>
      </ref>
      <ref id="CR3">
        <label>3.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Vahedi</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Hofmeijer</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Juettler</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Vicaut</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>George</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Algra</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Amelink</surname>
              <given-names>GJ</given-names>
            </name>
            <name>
              <surname>Schmiedeck</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Schwab</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Rothwell</surname>
              <given-names>PM</given-names>
            </name>
            <name>
              <surname>Bousser</surname>
              <given-names>MG</given-names>
            </name>
            <name>
              <surname>van der Worp</surname>
              <given-names>HB</given-names>
            </name>
            <name>
              <surname>Hacke</surname>
              <given-names>W</given-names>
            </name>
          </person-group>
          <article-title>Early decompressive surgery in malignant infarction of the middle cerebral artery: a pooled analysis of three randomised controlled trials</article-title>
          <source>Lancet neurology</source>
          <year>2007</year>
          <volume>6</volume>
          <issue>3</issue>
          <fpage>215</fpage>
          <lpage>222</lpage>
          <pub-id pub-id-type="doi">10.1016/S1474-4422(07)70036-4</pub-id>
        </element-citation>
      </ref>
      <ref id="CR4">
        <label>4.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Walcott</surname>
              <given-names>BP</given-names>
            </name>
            <name>
              <surname>Kahle</surname>
              <given-names>KT</given-names>
            </name>
            <name>
              <surname>Simard</surname>
              <given-names>JM</given-names>
            </name>
          </person-group>
          <article-title>Novel treatment targets for cerebral edema</article-title>
          <source>Neurotherapeutics</source>
          <year>2012</year>
          <volume>9</volume>
          <issue>1</issue>
          <fpage>65</fpage>
          <lpage>72</lpage>
          <pub-id pub-id-type="doi">10.1007/s13311-011-0087-4</pub-id>
          <pub-id pub-id-type="pmid">22125096</pub-id>
        </element-citation>
      </ref>
      <ref id="CR5">
        <label>5.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Strandvik</surname>
              <given-names>GF</given-names>
            </name>
          </person-group>
          <article-title>Hypertonic saline in critical care: a review of the literature and guidelines for use in hypotensive states and raised intracranial pressure</article-title>
          <source>Anaesthesia</source>
          <year>2009</year>
          <volume>64</volume>
          <issue>9</issue>
          <fpage>990</fpage>
          <lpage>1003</lpage>
          <pub-id pub-id-type="doi">10.1111/j.1365-2044.2009.05986.x</pub-id>
          <pub-id pub-id-type="pmid">19686485</pub-id>
        </element-citation>
      </ref>
      <ref id="CR6">
        <label>6.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Barreca</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Gandolfo</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Corsini</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Del Sette</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Cataldi</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Rolandi</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Franceschini</surname>
              <given-names>R</given-names>
            </name>
          </person-group>
          <article-title>Evaluation of the secretory pattern of plasma arginine vasopressin in stroke patients</article-title>
          <source>Cerebrovasc Dis</source>
          <year>2001</year>
          <volume>11</volume>
          <issue>2</issue>
          <fpage>113</fpage>
          <lpage>118</lpage>
          <pub-id pub-id-type="doi">10.1159/000047622</pub-id>
          <pub-id pub-id-type="pmid">11223663</pub-id>
        </element-citation>
      </ref>
      <ref id="CR7">
        <label>7.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Chang</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Chen</surname>
              <given-names>TY</given-names>
            </name>
            <name>
              <surname>Chen</surname>
              <given-names>CH</given-names>
            </name>
            <name>
              <surname>Crain</surname>
              <given-names>BJ</given-names>
            </name>
            <name>
              <surname>Toung</surname>
              <given-names>TJ</given-names>
            </name>
            <name>
              <surname>Bhardwaj</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
          <article-title>Plasma arginine-vasopressin following experimental stroke: effect of osmotherapy</article-title>
          <source>J Appl Physiol (1985)</source>
          <year>2006</year>
          <volume>100</volume>
          <issue>5</issue>
          <fpage>1445</fpage>
          <lpage>1451</lpage>
          <pub-id pub-id-type="doi">10.1152/japplphysiol.00763.2005</pub-id>
          <pub-id pub-id-type="pmid">16339345</pub-id>
        </element-citation>
      </ref>
      <ref id="CR8">
        <label>8.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Vakili</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Kataoka</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Plesnila</surname>
              <given-names>N</given-names>
            </name>
          </person-group>
          <article-title>Role of arginine vasopressin V1 and V2 receptors for brain damage after transient focal cerebral ischemia</article-title>
          <source>J Cerebr Blood Flow Metabol</source>
          <year>2005</year>
          <volume>25</volume>
          <issue>8</issue>
          <fpage>1012</fpage>
          <lpage>1019</lpage>
          <pub-id pub-id-type="doi">10.1038/sj.jcbfm.9600097</pub-id>
        </element-citation>
      </ref>
      <ref id="CR9">
        <label>9.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Decaux</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Soupart</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Vassart</surname>
              <given-names>G</given-names>
            </name>
          </person-group>
          <article-title>Non-peptide arginine-vasopressin antagonists: the vaptans</article-title>
          <source>Lancet</source>
          <year>2008</year>
          <volume>371</volume>
          <issue>9624</issue>
          <fpage>1624</fpage>
          <lpage>1632</lpage>
          <pub-id pub-id-type="doi">10.1016/S0140-6736(08)60695-9</pub-id>
          <pub-id pub-id-type="pmid">18468546</pub-id>
        </element-citation>
      </ref>
      <ref id="CR10">
        <label>10.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Walter</surname>
              <given-names>KA</given-names>
            </name>
          </person-group>
          <article-title>Conivaptan: new treatment for hyponatremia</article-title>
          <source>Am J Health Syst Pharm</source>
          <year>2007</year>
          <volume>64</volume>
          <issue>13</issue>
          <fpage>1385</fpage>
          <lpage>1395</lpage>
          <pub-id pub-id-type="doi">10.2146/ajhp060383</pub-id>
          <pub-id pub-id-type="pmid">17592003</pub-id>
        </element-citation>
      </ref>
      <ref id="CR11">
        <label>11.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Okuno</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Taya</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Marmarou</surname>
              <given-names>CR</given-names>
            </name>
            <name>
              <surname>Ozisik</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Fazzina</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Kleindienst</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Gulsen</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Marmarou</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
          <article-title>The modulation of aquaporin-4 by using PKC-activator (phorbol myristate acetate) and V1a receptor antagonist (SR49059) following middle cerebral artery occlusion/reperfusion in the rat</article-title>
          <source>Acta Neurochirurgica Supplement</source>
          <year>2008</year>
          <volume>102</volume>
          <fpage>431</fpage>
          <lpage>436</lpage>
          <pub-id pub-id-type="doi">10.1007/978-3-211-85578-2_84</pub-id>
          <pub-id pub-id-type="pmid">19388361</pub-id>
        </element-citation>
      </ref>
      <ref id="CR12">
        <label>12.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Aditya</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Rattan</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
          <article-title>Vaptans: a new option in the management of hyponatremia</article-title>
          <source>Int J Basic Appl Innovat Res</source>
          <year>2012</year>
          <volume>2</volume>
          <issue>2</issue>
          <fpage>77</fpage>
          <lpage>83</lpage>
          <pub-id pub-id-type="doi">10.4103/2229-516X.106347</pub-id>
        </element-citation>
      </ref>
      <ref id="CR13">
        <label>13.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Hline</surname>
              <given-names>SS</given-names>
            </name>
            <name>
              <surname>Pham</surname>
              <given-names>PT</given-names>
            </name>
            <name>
              <surname>Pham</surname>
              <given-names>PT</given-names>
            </name>
            <name>
              <surname>Aung</surname>
              <given-names>MH</given-names>
            </name>
            <name>
              <surname>Pham</surname>
              <given-names>PM</given-names>
            </name>
            <name>
              <surname>Pham</surname>
              <given-names>PC</given-names>
            </name>
          </person-group>
          <article-title>Conivaptan: a step forward in the treatment of hyponatremia?</article-title>
          <source>Therapeut Clin Risk Manag</source>
          <year>2008</year>
          <volume>4</volume>
          <issue>2</issue>
          <fpage>315</fpage>
          <lpage>326</lpage>
        </element-citation>
      </ref>
      <ref id="CR14">
        <label>14.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Potts</surname>
              <given-names>MB</given-names>
            </name>
            <name>
              <surname>DeGiacomo</surname>
              <given-names>AF</given-names>
            </name>
            <name>
              <surname>Deragopian</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Blevins</surname>
              <given-names>LS</given-names>
              <suffix>Jr</suffix>
            </name>
          </person-group>
          <article-title>Use of intravenous conivaptan in neurosurgical patients with hyponatremia from syndrome of inappropriate antidiuretic hormone secretion</article-title>
          <source>Neurosurgery</source>
          <year>2011</year>
          <volume>69</volume>
          <issue>2</issue>
          <fpage>268</fpage>
          <lpage>273</lpage>
          <pub-id pub-id-type="pmid">21792136</pub-id>
        </element-citation>
      </ref>
      <ref id="CR15">
        <label>15.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Jones</surname>
              <given-names>RC</given-names>
            </name>
            <name>
              <surname>Rajasekaran</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Rayburn</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Tobias</surname>
              <given-names>JD</given-names>
            </name>
            <name>
              <surname>Kelsey</surname>
              <given-names>RM</given-names>
            </name>
            <name>
              <surname>Wetzel</surname>
              <given-names>GT</given-names>
            </name>
            <name>
              <surname>Cabrera</surname>
              <given-names>AG</given-names>
            </name>
          </person-group>
          <article-title>Initial experience with conivaptan use in critically ill infants with cardiac disease</article-title>
          <source>J Pediatr Pharmacol Therapeut</source>
          <year>2012</year>
          <volume>17</volume>
          <issue>1</issue>
          <fpage>78</fpage>
          <lpage>83</lpage>
        </element-citation>
      </ref>
      <ref id="CR16">
        <label>16.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Liu</surname>
              <given-names>X</given-names>
            </name>
            <name>
              <surname>Nakayama</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Amiry-Moghaddam</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Ottersen</surname>
              <given-names>OP</given-names>
            </name>
            <name>
              <surname>Bhardwaj</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
          <article-title>Arginine-vasopressin V1 but not V2 receptor antagonism modulates infarct volume, brain water content, and aquaporin-4 expression following experimental stroke</article-title>
          <source>Neurocritical care</source>
          <year>2010</year>
          <volume>12</volume>
          <issue>1</issue>
          <fpage>124</fpage>
          <lpage>131</lpage>
          <pub-id pub-id-type="doi">10.1007/s12028-009-9277-x</pub-id>
          <pub-id pub-id-type="pmid">19806476</pub-id>
        </element-citation>
      </ref>
      <ref id="CR17">
        <label>17.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Rosenberg</surname>
              <given-names>GA</given-names>
            </name>
            <name>
              <surname>Estrada</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Kyner</surname>
              <given-names>WT</given-names>
            </name>
          </person-group>
          <article-title>Vasopressin-induced brain edema is mediated by the V1 receptor</article-title>
          <source>Adv Neurol</source>
          <year>1990</year>
          <volume>52</volume>
          <fpage>149</fpage>
          <lpage>154</lpage>
          <pub-id pub-id-type="pmid">2144395</pub-id>
        </element-citation>
      </ref>
      <ref id="CR18">
        <label>18.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Shuaib</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Xu Wang</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Yang</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Noor</surname>
              <given-names>R</given-names>
            </name>
          </person-group>
          <article-title>Effects of nonpeptide V(1) vasopressin receptor antagonist SR-49059 on infarction volume and recovery of function in a focal embolic stroke model</article-title>
          <source>Stroke</source>
          <year>2002</year>
          <volume>33</volume>
          <issue>12</issue>
          <fpage>3033</fpage>
          <lpage>3037</lpage>
          <pub-id pub-id-type="doi">10.1161/01.STR.0000039405.31526.06</pub-id>
          <pub-id pub-id-type="pmid">12468809</pub-id>
        </element-citation>
      </ref>
      <ref id="CR19">
        <label>19.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Manaenko</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Fathali</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Khatibi</surname>
              <given-names>NH</given-names>
            </name>
            <name>
              <surname>Lekic</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Hasegawa</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Martin</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Tang</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Zhang</surname>
              <given-names>JH</given-names>
            </name>
          </person-group>
          <article-title>Arginine-vasopressin V1a receptor inhibition improves neurologic outcomes following an intracerebral hemorrhagic brain injury</article-title>
          <source>Neurochem Int</source>
          <year>2011</year>
          <volume>58</volume>
          <issue>4</issue>
          <fpage>542</fpage>
          <lpage>548</lpage>
          <pub-id pub-id-type="doi">10.1016/j.neuint.2011.01.018</pub-id>
          <pub-id pub-id-type="pmid">21256175</pub-id>
        </element-citation>
      </ref>
      <ref id="CR20">
        <label>20.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Manaenko</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Fathali</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Khatibi</surname>
              <given-names>NH</given-names>
            </name>
            <name>
              <surname>Lekic</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Shum</surname>
              <given-names>KJ</given-names>
            </name>
            <name>
              <surname>Martin</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Zhang</surname>
              <given-names>JH</given-names>
            </name>
            <name>
              <surname>Tang</surname>
              <given-names>J</given-names>
            </name>
          </person-group>
          <article-title>Post-treatment with SR49059 improves outcomes following an intracerebral hemorrhagic stroke in mice</article-title>
          <source>Acta Neurochirurgica Supplement</source>
          <year>2011</year>
          <volume>111</volume>
          <fpage>191</fpage>
          <lpage>196</lpage>
          <pub-id pub-id-type="doi">10.1007/978-3-7091-0693-8_32</pub-id>
          <pub-id pub-id-type="pmid">21725754</pub-id>
        </element-citation>
      </ref>
      <ref id="CR21">
        <label>21.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Salvucci</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Armstead</surname>
              <given-names>WM</given-names>
            </name>
          </person-group>
          <article-title>Vasopressin impairs K(ATP) and K(ca) channel function after brain injury</article-title>
          <source>Brain Res</source>
          <year>2000</year>
          <volume>887</volume>
          <issue>2</issue>
          <fpage>406</fpage>
          <lpage>412</lpage>
          <pub-id pub-id-type="doi">10.1016/S0006-8993(00)03079-1</pub-id>
          <pub-id pub-id-type="pmid">11134631</pub-id>
        </element-citation>
      </ref>
      <ref id="CR22">
        <label>22.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Croiset</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>De Wied</surname>
              <given-names>D</given-names>
            </name>
          </person-group>
          <article-title>Proconvulsive effect of vasopressin; mediation by a putative V2 receptor subtype in the central nervous system</article-title>
          <source>Brain Res</source>
          <year>1997</year>
          <volume>759</volume>
          <issue>1</issue>
          <fpage>18</fpage>
          <lpage>23</lpage>
          <pub-id pub-id-type="doi">10.1016/S0006-8993(97)00070-X</pub-id>
          <pub-id pub-id-type="pmid">9219858</pub-id>
        </element-citation>
      </ref>
      <ref id="CR23">
        <label>23.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Landgraf</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Ramirez</surname>
              <given-names>AD</given-names>
            </name>
            <name>
              <surname>Ramirez</surname>
              <given-names>VD</given-names>
            </name>
          </person-group>
          <article-title>The positive feedback action of vasopressin on its own release from rat septal tissue in vitro is receptor-mediated</article-title>
          <source>Brain Res</source>
          <year>1991</year>
          <volume>545</volume>
          <issue>1&#x2013;2</issue>
          <fpage>137</fpage>
          <lpage>141</lpage>
          <pub-id pub-id-type="doi">10.1016/0006-8993(91)91279-A</pub-id>
          <pub-id pub-id-type="pmid">1830507</pub-id>
        </element-citation>
      </ref>
      <ref id="CR24">
        <label>24.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Wotjak</surname>
              <given-names>CT</given-names>
            </name>
            <name>
              <surname>Ludwig</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Landgraf</surname>
              <given-names>R</given-names>
            </name>
          </person-group>
          <article-title>Vasopressin facilitates its own release within the rat supraoptic nucleus in vivo</article-title>
          <source>Neuroreport</source>
          <year>1994</year>
          <volume>5</volume>
          <issue>10</issue>
          <fpage>1181</fpage>
          <lpage>1184</lpage>
          <pub-id pub-id-type="doi">10.1097/00001756-199406020-00005</pub-id>
          <pub-id pub-id-type="pmid">7919160</pub-id>
        </element-citation>
      </ref>
      <ref id="CR25">
        <label>25.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Yeung</surname>
              <given-names>PK</given-names>
            </name>
            <name>
              <surname>Lo</surname>
              <given-names>AC</given-names>
            </name>
            <name>
              <surname>Leung</surname>
              <given-names>JW</given-names>
            </name>
            <name>
              <surname>Chung</surname>
              <given-names>SS</given-names>
            </name>
            <name>
              <surname>Chung</surname>
              <given-names>SK</given-names>
            </name>
          </person-group>
          <article-title>Targeted overexpression of endothelin-1 in astrocytes leads to more severe cytotoxic brain edema and higher mortality</article-title>
          <source>J Cerebr Blood Flow Metabol</source>
          <year>2009</year>
          <volume>29</volume>
          <issue>12</issue>
          <fpage>1891</fpage>
          <lpage>1902</lpage>
          <pub-id pub-id-type="doi">10.1038/jcbfm.2009.175</pub-id>
        </element-citation>
      </ref>
      <ref id="CR26">
        <label>26.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Laszlo</surname>
              <given-names>FA</given-names>
            </name>
            <name>
              <surname>Varga</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Nakamura</surname>
              <given-names>S</given-names>
            </name>
          </person-group>
          <article-title>Vasopressin receptor antagonist OPC-31260 prevents cerebral oedema after subarachnoid haemorrhage</article-title>
          <source>Eur J Pharmacol</source>
          <year>1999</year>
          <volume>364</volume>
          <issue>2&#x2013;3</issue>
          <fpage>115</fpage>
          <lpage>122</lpage>
          <pub-id pub-id-type="doi">10.1016/S0014-2999(98)00836-X</pub-id>
          <pub-id pub-id-type="pmid">9932713</pub-id>
        </element-citation>
      </ref>
      <ref id="CR27">
        <label>27.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ameli</surname>
              <given-names>PA</given-names>
            </name>
            <name>
              <surname>Ameli</surname>
              <given-names>NJ</given-names>
            </name>
            <name>
              <surname>Gubernick</surname>
              <given-names>DM</given-names>
            </name>
            <name>
              <surname>Ansari</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Mohan</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Satriotomo</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Buckley</surname>
              <given-names>AK</given-names>
            </name>
            <name>
              <surname>Maxwell</surname>
              <given-names>CW</given-names>
              <suffix>Jr</suffix>
            </name>
            <name>
              <surname>Nayak</surname>
              <given-names>VH</given-names>
            </name>
            <name>
              <surname>Shushrutha Hedna</surname>
              <given-names>V</given-names>
            </name>
          </person-group>
          <article-title>Role of vasopressin and its antagonism in stroke related edema</article-title>
          <source>J Neurosci Res</source>
          <year>2014</year>
          <volume>92</volume>
          <issue>9</issue>
          <fpage>1091</fpage>
          <lpage>1099</lpage>
          <pub-id pub-id-type="doi">10.1002/jnr.23407</pub-id>
          <pub-id pub-id-type="pmid">24823792</pub-id>
        </element-citation>
      </ref>
    </ref-list>
  </back>
</article>
</pmc-articleset>
